Zymeworks, Inc. (ZYME)
28.77
+0.10
(+0.35%)
USD |
NASDAQ |
Aug 24, 16:00
29.00
+0.23
(+0.80%)
After-Hours: 20:00
Zymeworks Total Assets (Quarterly) : 396.96M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 396.96M |
| March 31, 2026 | 478.22M |
| December 31, 2025 | 346.53M |
| September 30, 2025 | 397.27M |
| June 30, 2025 | 408.38M |
| March 31, 2025 | 425.52M |
| December 31, 2024 | 463.09M |
| September 30, 2024 | 487.15M |
| June 30, 2024 | 515.63M |
| March 31, 2024 | 553.75M |
| December 31, 2023 | 580.88M |
| September 30, 2023 | 556.37M |
| June 30, 2023 | 602.05M |
| March 31, 2023 | 600.74M |
| December 31, 2022 | 648.72M |
| September 30, 2022 | 300.26M |
| June 30, 2022 | 368.97M |
| March 31, 2022 | 429.98M |
| December 31, 2021 | 389.13M |
| Date | Value |
|---|---|
| September 30, 2021 | 420.36M |
| June 30, 2021 | 471.95M |
| March 31, 2021 | 490.06M |
| December 31, 2020 | 538.38M |
| September 30, 2020 | 571.72M |
| June 30, 2020 | 606.85M |
| March 31, 2020 | 636.58M |
| December 31, 2019 | 368.20M |
| September 30, 2019 | 400.04M |
| June 30, 2019 | 414.55M |
| March 31, 2019 | 238.28M |
| December 31, 2018 | 244.36M |
| September 30, 2018 | 194.44M |
| June 30, 2018 | 211.00M |
| March 31, 2018 | 113.54M |
| December 31, 2017 | 131.96M |
| September 30, 2017 | 99.72M |
| June 30, 2017 | 114.54M |
| March 31, 2017 | 80.05M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Theravance Biopharma, Inc. | 469.77M |
| BridgeBio Pharma, Inc. | 1.217B |
| Aprea Therapeutics, Inc. | 42.29M |
| ACADIA Pharmaceuticals, Inc. | 1.743B |
| Alnylam Pharmaceuticals, Inc. | 5.559B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 316.60M |
| Shareholders Equity (Quarterly) | 80.37M |
| Debt to Equity Ratio | 3.343 |
| Current Ratio | 6.316 |
| Net Debt Paydown Yield | -2.66% |